Posted in Africa Press Releases South Africa

Première biopsie liquide à recevoir l’approbation de la FDA pour le profilage complet des tumeurs dans tous les cancers solides, le diagnostic compagnon Guardant360® de Guardant Health gagne en crédibilité auprès des oncologues en Asie, au Moyen-Orient et en Afrique.

SINGAPOUR, 8 août 2020 /PRNewswire/ — La Food and Drug Administration (FDA) des États-Unis a approuvé la biopsie liquide de Guardant Health, le diagnostic compagnon Guardant360®, pour le profilage des mutations tumorales chez les patients atteints de toutes sortes de cancers solides. Pour Guardant Health Asia, Middle East and Africa (AMEA), cette approbation de la FDA […]

Read More Première biopsie liquide à recevoir l’approbation de la FDA pour le profilage complet des tumeurs dans tous les cancers solides, le diagnostic compagnon Guardant360® de Guardant Health gagne en crédibilité auprès des oncologues en Asie, au Moyen-Orient et en Afrique.
Posted in Health Care

AU: ‘Aggressive, Bold’ Action Needed to Combat COVID-19 in Africa

The African Union says “aggressive and bold” action is needed to combat the COVID-19 outbreak on the continent. More than one million cases of the…

Read More AU: ‘Aggressive, Bold’ Action Needed to Combat COVID-19 in Africa
Posted in General

Can the Takuba Force Turn Around the Sahel Conflict?

Two years after a pan-European military initiative was first proposed to help tackle the Sahel’s Islamist insurgency, the Takuba task force is finally becoming reality,…

Read More Can the Takuba Force Turn Around the Sahel Conflict?
Posted in Health Care

Suicide Bombing on Somalia Military Base Kills Nine

At least nine people were killed and nearly 20 others injured Saturday in a car bomb blast at the front gate of a Somali military…

Read More Suicide Bombing on Somalia Military Base Kills Nine
Posted in Africa MENA Press Releases South Africa

First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health’s Guardant360® CDx, gains credibility among oncologists in Asia, Middle East and Africa.

SINGAPORE, Aug. 8, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Guardant Health’s liquid biopsy, Guardant360® CDx, for tumor mutation profiling in patients across all solid cancers. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval represents a landmark achievement for the Guardant360 test. Currently, the liquid biopsy is […]

Read More First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health’s Guardant360® CDx, gains credibility among oncologists in Asia, Middle East and Africa.